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Results expression of ghRh was found to be positive 
in 61.9 % of samples. pghRh receptor was not expressed 
in our sample set, while sV1 could be detected in 17.4 % 
and sV2 in 8.6 % of the gB tissues. In 65.2 and 78.3 % 
of samples, significant egFR over-expression or Pten 
under-representation could be detected, respectively. In 
47.8 % of cases, egFR up-regulation and Pten down-reg-
ulation occurred together. survival was significantly poorer 
in tumors lacking ghRh expression. this worse prognosis 
in ghRh negative group remained significant even if sV1 
was also expressed.
Conclusion Our study shows that ghRh and sV1 genes 
expressed in human gB samples and their expression pat-
terns are associated with poorer prognosis.
Keywords ghRh · pghRhR · splice variants · sV1 · 
egFR · Pten · human glioblastoma
Abstract 
Purpose glioblastoma (gB) is the most frequent brain 
tumor. Despite recent improvement in therapeutic strategies, 
the prognosis of gB remains poor. growth hormone-releas-
ing hormone (ghRh) may act as a growth factor; antagonists 
of ghRh have been successfully applied for experimental 
treatment of different types of tumors. the expression profile 
of ghRh receptor, its main splice variant sV1 and ghRh 
have not been investigated in human gB tissue samples.
Methods We examined the expression of ghRh, full-
length pituitary-type ghRh receptor (pghRhR), its func-
tional splice variant sV1 and non-functional sV2 by Rt-
PCR in 23 human gB specimens. epidermal growth factor 
receptor (egFR) and phosphatase and tensin homolog gene 
(Pten) expression levels were also evaluated by quantita-
tive Rt-PCR. Correlations between clinico-pathological 
parameters and gene expressions were analyzed.
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Introduction
glioblastoma (gB) is the most frequent primary human 
brain tumor (louis et al. 2007). although recent thera-
peutic strategies have shown moderate effect on the over-
all survival time for patients with gB (stupp et al. 2005), 
its prognosis remains poor because of the high infiltrating 
potential and the limited efficacy of surgical and oncologi-
cal treatments. In the majority of the cases, gB emerged as 
primary gB without any clinical or histological evidence of 
a less malignant precursor lesion (secondary gB). In spite 
of numerous attempts to identify molecular prognostic fac-
tors, the relevant prognostic indicators still remain age, 
performance score and extent of surgical resection (Weller 
et al. 2009). In general, the invasive potential of gB highly 
restricts the efficacy of surgery, and the recently adopted 
combination of temozolamide chemotherapy and radiother-
apy are neither specific nor selective for this type of tumor 
(stupp et al. 2005).
the most common genetic abnormality in gliomagenesis 
is the activation of receptor tyrosine kinases (RtKs), spe-
cifically the aberrant expression of epidermal growth factor 
receptor (egFR) (Cancer genome atlas Research network 
2008). In line with egFR gene amplification events, there 
is an increase in intragenic in-frame deletion of exons 2–7 
of the egFR gene (Zhu et al. 2009). this mutated egFR, 
known as egFRv3, is a constitutively activated, ligand-
independent receptor. In addition, the amplification of the 
egFR locus leads to the co- and over-expression of wild 
type (wt) and v3 within the same cells (Zhu et al. 2009). 
however, the over-expression of wt egFR or v3 alone is 
not a transforming event in adult brain tissues (Zhu et al. 
2009). an extensive molecular characterization of human 
gBs revealed a finite number of genetic aberration in which 
RtKs are activated concomitantly with the loss of tumor 
suppressor gene functions, such as those encoded by phos-
phatase and tensin homolog gene (Pten). Pten is located 
on chromosome 10q which is the most frequently lost chro-
mosome in gBs, occurring in up to 85 % of cases (steck 
et al. 1997; li et al. 1997; Knobbe et al. 2002). Recently, it 
has been shown that loss of Pten in gB leads to the devel-
opment of resistance to therapy with egFR kinase inhibitor 
agents (Mellinghoff et al. 2005).
the gene for pituitary-type growth hormone-releasing 
hormone receptor (pghRhR) is located on chromosome 
7p, near egFR. the presence of growth hormone-releas-
ing hormone (ghRh) has been shown to act as a growth 
factor in various cancers (schally et al. 2008; schally and 
halmos 2012). Moreover, antagonists of ghRh have been 
applied successfully for the treatment of different types of 
tumors, including malignant gliomas (schally et al. 2008; 
schally and halmos 2012; schally and Varga 1999, 2006; 
Pozsgai et al. 2010; Jaszberenyi et al. 2013). however, the 
expression profiles of ghRh receptor and its main splice 
variant, sV1 has not been investigated in human gB tissue 
samples. In this study, we examined the mRna expression 
of ghRh, its two functional receptors, pghRhR and sV1, 
and non-functional splice variant sV2 in 23 human gB tis-
sues. We also determined the egFR and Pten expression 
levels in our sample set. since detailed clinical history with 
complete follow-up was also available, correlations could 
be analyzed between clinico-pathological parameters and 
gene expressions.
Materials and methods
tissue samples
twenty-six tissue samples (23 glioblastomas and 3 peritu-
moral tissues) were collected during neurosurgical opera-
tions in the Department of neurosurgery, University of 
Debrecen, hungary. the samples were frozen immediately 
after removal in liquid nitrogen and stored at −80 °C until 
processing. sections were cut from the same samples for 
histological analysis and genetic investigations. lesions 
were diagnosed on the basis of formalin-fixed paraffin-
embedded (FFPe) tissue sections by hematoxylin-eosin 
staining and by additional immunohistochemistry. Classifi-
cation of tumors was based on the World health Organi-
zation International Classification of tumours 2007 (louis 
et al. 2007). the local institutional ethics committee 
approved the collection and use of these specimens for the 
current study and informed consent was obtained from all 
patients.
Rna extraction and Rt-PCR for detecting ghRh, 
pghRhR, sV1 and sV2
Frozen tissue samples were incubated overnight at −20 °C 
in Rnalater Ice solution (Qiagen, gmbh, germany). Rne-
asy mini kit (Qiagen, gmbh, germany) was used to isolate 
total Rna from tissue samples. Rna quantity and quality 
were determined by nanoDrop nD-1000 UV–Vis spec-
trophotometer (nanoDrop technologies, Wilmington, De) 
and 1 % tae agarose gel. two hundred fifty nanograms 
of Rna from each sample were reverse transcribed into 
cDna by Quantitect Reverse transcription kit (Qiagen) in 
a final volume of 20 μl. the integrity of cDna was tested 
by Rt-PCR for β-actin (aCtB). gene-specific primers for 
pghRh-R (sense: 5′-CaCgtCttCtgCgtgttgag-3′, 
antisense: 5′-gCatCtCCtCtgCtgCttgt-3′) and sV1 
(sense: 5′-ggagttgtggCtagagag-3′, antisense: 
5′-gCatagaaCagtggagaag-3′) were designed with 
the primer3_www.cgi v0.2 program (Rozen and skaletsky 
2000), and primers for ghRh and aCtB were described 
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previously (havt et al. 2005; Øvstebø et al. 2003). In all 
Rt-PCR reactions, 1 μl of cDna was amplified in a 
25 μl solution containing 1.5 mM MgCl2, 1× PCR buffer 
(Fermentas, germany), 0.3 mM of each deoxynucleotide 
(Promega, germany), 1 unit of truestart hotstart Dna 
polymerase (Fermentas) and 0.25 μM of each primer. sam-
ples were denatured for 3 min at 95 °C, then subjected to 
30 (aCtB) or 40 cycles of 95 °C for 45 s, 54 °C (sV1), 
59 °C (sV2) 64 °C (ghRh) or 67 °C (pghRhR) for 30 s, 
then 72 °C for 1.5 min with a final extension of 10 min at 
72 °C; 10 μl of each amplification reaction was electropho-
retically separated on 1.5 % agarose gel, stained with eth-
idium bromide, and visualized under UV light (Fig. 1).
Quantitative Rt-PCR for detecting egFR and Pten
six hundred nanogram of Rna from each sample was 
translated into cDna applying high Capacity cDna 
Reverse transcription kit (applied Biosystems, Ca, 
Usa) according to the manufacturer’s instructions. sYBR 
green Premix ex taq-based assay was used to determine 
the mRna expression level of egFR and Pten genes 
(takara Bio Inc., Japan). For the analysis, the follow-
ing primers were used, each in 0.25 μM final concentra-
tion: egFR (forward: 5′-CtC agC CaC CCa tat gta 
CC-3′; reverse: 5′-Cgt CCa tgt Ctt Ctt Cat CC-3′), 
Pten (forward: 5′-agC atC aCC att Ctt tgC tg-3′; 
reverse: 5′-aCC aCa gCC atC gtt atg aa-3′) and 
gaPDh (forward: 5′-Cag tCa aCg gat ttg gtC 
gt-3′; reverse: 5′-ttg att ttg gag gga tCt Cg-3′). 
each reaction contained 15 ng cDna and was run in trip-
licate on M×3005P™ real-time PCR system (agilent 
technologies, Usa) with the following thermal profile: 
activation at 95 °C for 1 min; 40 cycles of amplification 
at 95 °C for 1 min, at 55 °C (gaPDh), 58 °C (egFR) or 
60 °C (Pten) for 30 s followed by 72 °C for 1 min. Melt-
ing curve analysis was also performed in each case. Fold 
changes in gene expression were calculated by the ΔΔCt 
method (livak and schmittgen 2001) using gaPDh as 
internal control and peritumoral tissue sample as calibrator.
statistical analysis
For statistical analysis, the IBM sPss statistics 19 software 
(IBM Corporation, Usa) was used. In cases of egFR and 
Pten, more than twofold change in the gene expression 
level was considered as gene down- or up-regulation. On 
the basis of the Kolmogorov–smirnov test, the distribution 
of egFR expression data is significantly different from a 
normal one so nonparametric tests were applied to compare 
the mRna expression levels of egFR (Mann–Whitney U 
test), Pten (independent samples median test) genes and 
Fig. 1  ghRh ligand and receptor expressions in gB samples. Representative gel photos of mRna expression of a pghRhR, b ghRh, 
c splicing variant, sV1; + positive control (human pituitary), − negative control; no. 1–8 gB samples
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the expression profiles of ghRh, sV1 and clinico-patho-
logical data. Kaplan–Meier method with log rank (Mantel–
Cox) test was used for survival analysis. Differences with 
p < 0.05 were considered statistically significant.
Results
Clinical course of the patients
twenty-three patients suffering from primary gB were 
operated in our department during the period of novem-
ber 2005 and november 2008. samples from their resected 
solid tumors were studied. the largest tumor diameter was 
>3 centimeters in all cases. In case of 15 patients, the oper-
ation was performed at the first recognition of the tumor. 
after surgery, standard postoperative treatment was initi-
ated. the postoperative treatment was canceled in four 
cases because of the rapid progression of the tumor and, in 
one case, because of non-compliance by the patient. eight 
of the 23 patients had previous surgery and received regu-
lar postoperative treatment for proven gB histology. In 
these cases, samples were collected at the reoperation of 
the tumor recurrence. In four of these cases, we also had 
samples from the first operation. In 3 cases, we obtained 
peritumoral tissues, which required removal to facilitate 
approach to the tumors themselves. these tissues were 
used for calibration in subsequently measuring egFR and 
Pten expression levels.
the mean age of the patients sampled was 59.8 
years ± 2.2 se (range 37–78 years), with 14:9 ratio of 
female to male. the follow-up lasted until the death of 
the last patient (June 2011). Mean overall survival was 
536.3 days ± 107.0 se (n = 19) from diagnosis, and mean 
survival from sampling was 411.3 days ± 90.3 se (n = 23). 
the four operated and later reoperated patients were calcu-
lated, of course, as one patient in the relevant statistics. all 
of the patients died because of tumor progression. Clinico-
pathological data of patients are summarized in table 1.
expression of pghRhR, sV1, sV2 and ghRh in human 
gB samples
Pituitary-type ghRh (pghRhR) receptor was not 
expressed in our sample set while sV1 could be detected in 
17.4 % of the tissues (4 out of 23). another—presumably 
non-functional—splice variant, sV2, could be detected in 2 
samples (8.6 %).
to examine the possible autocrine and paracrine effect 
of the natural ligand, the expression of ghRh was also 
determined and found to be positive in 14 samples out of 
23 (61.9 %). Only one sample expressed both the ligand 
ghRh and receptor sV1. among the 9 of 23 ghRh 
negative samples, three were positive for sV1. Constella-
tions of pghRhR, sV1, sV2 and ghRh expressions of 
samples were detailed in table 2.
expression levels of egFR and Pten
the expression levels of egFR and Pten genes were pre-
sented as normalized data as it was written in the “Mate-
rials and methods” section. In 15 of 23 samples (65.2 %), 
significant egFR over-expression could be detected, and 
18 samples showed significant Pten gene under-repre-
sentation (78.3 %). In case of 11 patients (47.8 %), egFR 
up-regulation was accompanied by Pten down-regulation. 
the results of gene expression analyses are presented in 
table 3.
expression profiles of samples from the same patient prior 
and after therapy
In case of 4 patients, we had the opportunity to take tumor 
samples both at the first operation and at surgery for recur-
rence. In 3 of these cases, ghRh was present in the initial 
tumor but could not be detected in the tumor tissue from the 
recurrence. sV1 was present in only one tumor at the time 
of first operation. egFR and Pten showed normal expres-
sion in only one tumor but also in this case, egFR was over-
expressed and Pten was down-regulated in the tissue of the 
recurrence. Otherwise, egFR mRna was over-represented 
in all samples and Pten was down-regulated in all but one 
recurrent tumor tissue. these results are shown in table 4.
analyses of gene expressions and clinico-pathological data
thorough statistical analyses of the studied expression 
levels we found that in sV1 positive samples the Pten 
expressions showed significantly increased levels com-
pared to sV1 negative cases.
For further analysis, we divided the patient into two 
groups. group 1 included 15 patients who were operated 
at clinical diagnosis, without previous treatment. group 2 
included 8 patients where the recurrent tumor was sampled 
after chemo-irradiation. Four patients were present in both 
groups as operated and later reoperated cases. In group 
1, patients with ghRh negative tumors had significantly 
decreased overall survival (Os). this decrease remained 
significant even in the presence of sV1 positivity (Fig. 2), 
which showed connection with higher median levels of 
Pten. In group 2, we did not find these correlations.
analysis of Os in the two groups together is question-
able because the overlapping four patients showed that 
the therapy and tumor progression might lead to changed 
genetic profile. however, analysis of Os in the combined 
two groups (excluding the four overlapping patients in 
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the second group) also revealed that the ghRh negative 
cases showed shorter Os, which was still significantly 
decreased in cases that were ghRh negative and sV1 
positive (Fig. 3). Conversely, ghRh positive and sV1 
negative cases showed better prognosis. egFR and Pten 
expression levels were not correlated significantly with Os. 
although, the lack of postoperative treatment itself seemed 
to lead to shorter survival time, in these cases rapid tumor 
progression produced a decrease in KPs (Karnofsky Per-
formance score) and led to cancelation of the suitable ther-
apy (which should have been used postoperatively).
Discussion
Despite the multiple multimodality treatment options, gB 
has the worst prognosis of any central nervous system 
tumors. to improve the survival, ghRh antagonists have 
been developed for the treatment of various human can-
cers (schally and Varga 1999; schally 2008; schally and 
halmos 2012). the efficacy of ghRh antagonists in 
experimental tumor models is due to the suppression of the 
pituitary gh-hepatic IgF axis and the direct blocking of 
binding of autocrine/paracrine ghRh to tumoral pghRh 
receptor and sV1-type receptor. It was demonstrated that 
ghRh antagonists bind specifically and with high affin-
ity to splice variants of the ghRh receptor present in 
many malignant tumors and produce direct antiprolifera-
tive effects by blocking the binding of autocrine ghRh to 
receptors (halmos et al. 2000, 2002). It was also proven 
that a peripherally administered ghRh analog (JV-1-42) 
can readily penetrate into the central nervous system (i.e., 
pass through the blood–brain barrier) (Jaeger et al. 2005). 
earlier it was shown that treatment with antagonistic 
Table 1  Main clinical characteristics of patients with primary gBM
Patients were divided into two groups: group 1 sampling at first recognition and group 2 sampling after previous treatment. a) and B) mean the 
same patient
CI chemo-irradiation, I irradiation, C temodal monotherapy, Op operation, sI histological sign of postirradiation changes
Patient 
number
gender age age at  
recognition
survival from  
first diagnosis  
(day)
Overall  
survival  
(day)
Initial  
localization
treatment 
before  
sampling
treatment 
after  
sampling
histology
group 1
1a F 64 same 702 same left temporal no CI, C gBM
2 F 67 same 156 same Right frontal no no gBM
3 M 73 same 280 same left temporo-parietal no I gBM
4 F 66 same 1738 same left frontal no CI, C gBM
5 F 66 same 112 same left occipital no CI gBM
6 F 63 same 662 same Right temporal no CI, C gBM
7a M 51 same 721 same left temporo-occipital no CI, C gBM
8a M 61 same 709 same left fronto-temporal no CI gBM
9 M 78 same 38 same left temporal no no gBM
10a M 52 same 715 same left frontal no CI, C gBM
11 M 59 same 90 same left frontal no no gBM
12 F 60 same 1231 same left temporal no CI gBM
13 F 44 same 65 same left temporo-parietal no no gBM
14 F 75 same 17 same left fronto-temporal no CI gBM
15 F 44 same 578 same left frontal no no gBM
group 2
1B F 65 64 264 702 left temporal CI, C C, I gBM sI
7B M 53 51 21 721 Right cerebellar CI, C C gBM sI
8B F 63 61 50 709 left parieto-occipital CI no gBM sI
10B M 52 52 566 715 left frontal CI, C Op gBM sI
16 F 37 37 196 364 left occipital Op, CI Op gBM sI
17 F 74 72 276 1209 left cerebellar Op, Op, I no gBM sI
18 M 58 57 85 400 Right frontal Op, Op, CI no gBM sI
19 F 51 50 187 402 Right fronto-temporal CI no gBM sI
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analogs of ghRh reduced the tumorigenicity of U-87gM 
human gB cells (Kiaris et al. 2000). the main splice vari-
ant receptor, sV1, is present in several tumor types (szepe-
shazi et al. 2000; Busto et al. 2002a, b; halmos et al. 2002). 
however, the presence of these two main functional ghRh 
receptors, pghRhR and sV1, has not been investigated in 
human gB tissue samples. In our study, 23 samples were 
obtained from primary gBs resected in the course of sur-
gery and were analyzed for the expression of ghRh and 
its receptors.
the egFR/Pten/akt/mtOR pathway is a key sign-
aling pathway in the development of primary glioblasto-
mas (Kita et al. 2007). amplification and/or over-expres-
sion of egFR occur in the majority of primary gBs (40 
and 60 %, respectively). Pten inhibits cell proliferation 
through PIP3 and is mutated in 15–40 % of gBs, almost 
exclusively in primary gBs (Ohgaki et al. 2004). although 
egFR and Pten seem to have a crucial role in gliom-
agenesis, their status neither predicted response to targeted 
therapies like everolimus and gefitinib nor it could be cor-
related with survival (Kreisl et al. 2009; ang et al. 2010). 
however, coexpression of egFRv3 and Pten in gB 
Table 2  expression of mRna of ghRh ligand and its receptors 
(pghRhR, sV1 and sV2) in human gB samples
group 1 sampling at first recognition and group 2 sampling after pre-
vious treatment. a) and B) mean the same patient; + expression, − 
no expression
Patient number pghRhR ghRh sV1 sV2
group 1
1a − + − −
2 − − − −
3 − + − +
4 − + − −
5 − + − −
6 − + − −
7a − + − −
8a − + + −
9 − − − +
10a − + − −
11 − − + −
12 − + − −
13 − + − −
14 − − + −
15 − − − −
group 2
1B − + − −
7B − − − −
8B − − − −
10B − − − −
16 − + − −
17 − + − −
18 − + − −
19 − − + −
Table 3  Relative expression levels of egFR and Pten genes
gaPDh normalized levels correlated with averages of peritumoral 
tissues (fold change level). More than twofold change in the gene 
expression levels was considered as gene down-/up-regulation indi-
cated by down or up arrows, respectively. group 1 sampling at first 
recognition and group 2 sampling after previous treatment. a) and B) 
mean the same patient
Patient number Relative expression levels
egFR ±se Pten ±se
group 1
1a 1.282 0.059 0.682 0.023
2 36.314 ↑ 0.464 0.424 ↓ 0.084
3 0.837 0.057 0.139 ↓ 0.004
4 0.112 ↓ 0.005 0.076 ↓ 0.001
5 3.279 ↑ 0.086 0.108 ↓ 0.006
6 0.356 ↓ 0.028 0.371 ↓ 0.011
7a 7.864 ↑ 0.365 0.246 ↓ 0.021
8a 143.479 ↑ 7.816 0.442 ↓ 0.014
9 11.743 ↑ 0.772 0.150 ↓ 0.021
10a 1.248 0.032 0.165 ↓ 0.007
11 1.238 0.077 0.410 ↓ 0.230
12 0.764 0.048 0.062 ↓ 0.002
13 2.468 ↑ 0.281 0.019 ↓ 0.001
14 4.039 ↑ 0.355 0.568 0.063
15 5.312 ↑ 0.096 0.211 ↓ 0.020
group 2
1B 2.084 ↑ 0.048 0.395 ↓ 0.005
7B 3.177 ↑ 0.122 0.417 ↓ 0.041
8B 16.380 ↑ 0.057 0.171 ↓ 0.021
10B 66.439 ↑ 0.691 1.772 0.043
16 2.620 ↑ 0.054 1.466 0.048
17 4.876 ↑ 0.068 0.914 0.019
18 5.493 ↑ 0.213 0.189 ↓ 0.011
19 0.342 ↓ 0.012 0.248 ↓ 0.039
Table 4  expression profiles of samples with recurrent tumors
a) samples from first operations, B) samples from recurrent tumors, 
↑ over-expression, ↓ down-regulation by real-time Rt-PCR
Patient number pghRhR ghRh sV1 egFR Pten
1a − + + ↑ ↓
1B − − − ↑ ↓
7a − + − no change no change
7B − + − ↑ ↓
8a − + − ↑ ↓
8B − − − ↑ ↓
10a − + − ↑ ↓
10B − − − ↑ no change
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cells was associated with responsiveness to egFR kinase 
inhibitors (Mellinghoff et al. 2005). In our study, we also 
evaluated classical gB markers such as egFR and Pten. 
Moreover, as the antiproliferative effect of ghRh antago-
nists was proven to act through the egFR-akt pathway in 
breast cancer cells (seitz et al. 2008), we looked for any 
Fig. 2  Correlation between expression of mRna of ghRh ligand 
and receptor sV1 and overall survival of the patients with newly 
diagnosed gB. a Correlation between ghRh expression and over-
all survival of the patients with newly diagnosed gB. Gray, dashed 
curve shows ghRh negative patients’ survival analysis; black, con-
tinuous curve represents ghRh positive cases (p = 0.004). b Cor-
relation between ghRh and sV1 expressions and overall survival 
of the patients with newly diagnosed gB. Gray, dashed curve shows 
ghRh negative, sV1 positive patients’ survival analysis; black 
dashed curve shows ghRh negative sV1 negative cases, gray con-
tinuous curve ghRh positive, sV1 positive cases; black, continuous 
curve represents ghRh positive, sV1 negative cases. (p = 0.008) 
Kaplan–Meier and log rank (Mantel–Cox) regression tests were used 
for survival analysis
Fig. 3  Correlation between expression of mRna of ghRh ligand 
and receptor sV1 and overall survival of the patients with newly 
diagnosed gBs and recurrent gBs together. a Correlation between 
ghRh expression and overall survival of the patients with newly 
diagnosed gBs and recurrent gBs together (group 1 and group 2). 
Gray, dashed curve shows ghRh negative; black continuous curve 
represents ghRh positive cases (p = 0.008). b Correlation between 
ghRh and sV1 expression and overall survival of the patients with 
newly diagnosed gBs and recurrent gBs together (group 1 and 
group 2). Gray, dashed curve shows ghRh negative, sV1 positive 
patients’ survival analysis; black dashed curve shows ghRh negative 
sV1 negative cases, gray continuous curve ghRh positive, sV1 pos-
itive cases; black, continuous curve represents ghRh positive, sV1 
negative cases. (p = 0.038). Kaplan–Meier and log rank (Mantel–
Cox) regression tests were used for survival analysis
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correlation between ghRh or its receptors and egFR, 
Pten.
according to our results, pituitary-type ghRh recep-
tor was not expressed in our sample set but sV1 could be 
detected in 17.4 % of the tissues. Moreover, in sV1 positive 
cases, the Pten expression levels significantly increased. 
the expression of ghRh was also determined and found 
to be positive in 61.9 % of the samples which suggests that 
ghRh has a role in the pathogenesis of gB. this is sup-
ported by previous studies, which reported improved cell 
survival of cardiac (granata et al. 2009) or tumoral cells 
(Pozsgai et al. 2010) following treatment with ghRh.
substantial statistical analysis of clinico-pathological 
data revealed a significantly negative correlation between 
prognoses and the lack of ghRh expression, and this 
remained significant if sV1 were also expressed. Con-
versely, ghRh positive, sV1 negative cases showed bet-
ter Os. It is partly supported by Farkas et al. (2012) who 
previously showed that the expression of ghRh-R was 
correlated with a poor response of rectal cancers to chemo-
therapy (Farkas et al. 2012).
this finding also suggests that not only paracrine and 
autocrine ghRh release could play a role in tumor pro-
gression through sV1 receptor activation and not only local 
intratumoral regulating factors may decrease the expres-
sion of tumoral ghRh. the tumorous ghRh expression, 
i.e., autocrine release of ghRh might be under influence 
of negative feedback effect. this effect may be based on 
down-regulation of ghRh expression through sV1 or 
other receptors mediated by systemic ghRh or other 
ligand. ghRh may signal through another receptor than 
sV1 and it could be protective. One of the presumed recep-
tors that could mediate the responses to ghRh might be 
receptors for VIP (vasoactive intestinal peptide), and these 
receptors might be protective as in the case of inhibitory 
effects of VIP on the growth of lung cancer (Maruno et al. 
1998). Renal cell carcinoma was also reported by Vacas 
et al. (2012) to be inhibited by VIP and PaCaP (pituitary 
adenylate cyclase-activating peptide) (Vacas et al. 2012).
Our study thus provides the first evidence that ghRh 
and sV1 are present in a substantial part of human gB 
tissues and support the merit of further investigation of 
ghRh pathway in this malignancy. Moreover, our result 
showed that ghRh and sV1 expression pattern of gB 
samples have significant correlation with overall survival.
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